A recent study by Chen et al. examined the anti-carcinoma potential of curcumin, treating PC3 and DU145 cells with a series of curcumin analogs of the second generation, in concentrations of 0–10 μM, founding the ability of curcumin to decrease the expression of NF-kB, mTOR (mammalian target of rapamycin), AKT and p-AKT [162]. Here, MTOR is linked to carcinoma.